✦ LIBER ✦

Imatinib Compared with Imatinib/Cytarabine for the First-Line Treatment of Early Philadelphia Chromosome–Positive Chronic Myeloid Leukemia: Results of a Randomized Clinical Trial of the Mexican Collaborative Leukemia Group

✍ Scribed by Hurtado-Monroy, Rafael; Vargas-Viveros, Pablo; Candelaria, Myrna; Cervera, Eduardo; Cruz, Judith; Gutierrez, Olga; Labardini, Juan

Book ID: 122899317
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 106 KB
Volume: 2
Category: Article
ISSN: 1931-6925
DOI: 10.3816/CLK.2008.n.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

High-dose imatinib versus high-dose imat

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

✍ Noortje Thielen, Bronno van der Holt, Gregor E. G. Verhoef… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 275 KB

Results of triple therapy with interfero

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l

PCN92 Cost-Effectiveness of Nilotinib Ve

PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN57 Cost Effectiveness of Nilotinib Ve

PCN57 Cost Effectiveness of Nilotinib Versus Imatinib as First Line Treatment for Newly Diagnosed Hong Kong (HK) Patients With Chronic Phase, Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Hong Kong

✍ Tse, V.; Liu, H.; Botteman, M.; Mcghee, S.; Lee, V.W.; Lee, K.K. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB